Cartagen Acquires BioMasher®
Distribution Rights From Nippi Inc.
SEATTLE, WA - February 14, 2005 - Cartagen
Molecular Systems, Inc. announced today
that it has entered into two key licensing
agreements with Nippi, Inc. (Tokyo, Japan)
focusing on Nippi’s innovative BioMasher
technology. These agreements provide Cartagen
exclusive sales and distribution rights
to the BioMasher technology in the United
States and Canada as well as rights to
incorporate the BioMasher technology into
Cartagen’s molecular biology kits
for worldwide distribution.
Founded in 1907, Nippi is a world leader
in the research and manufacturing of products
for the food and health industries. The
BioMasher technology was developed by
Nippi to rapidly prepare total cell lysates
for use in their diagnostic assay for
Bovine Spongiform Encephalitis (BSE),
commonly known as “Mad Cow Disease”.
In addition to research into the diagnosis
of BSE, Nippi was one of the pioneers
in the development of collagen-based health
and beauty products and continues to provide
leadership in this field.
"Nippi’s solution to the need
for creating rapid cell lysates is an
innovative breakthrough in sample preparation"
commented Steven Kirsher, President and
CEO of Cartagen. “The BioMasher
technology has proven to be a key enabling
technology in Nippi’s diagnostic
tests for BSE, and we have found that
the technology has broad potential in
the field of genomic and proteomic research.”
Working together with Nippi and R&D
partner, Investigen, Inc. (Hercules, CA),
Cartagen has already developed kits to
rapidly prepare PCR-ready DNA from plant
and insect tissue.
Cartagen Molecular Systems, Inc. was
founded in early 2003 to manufacture and
sell innovative reagent kits for life
science research. Based in Seattle, Washington,
the company focuses on providing competitively-priced
tools in convenient formats that enable
life scientists to perform selected key
techniques and methods which increase
the pace of their research.
|
